181
Participants
Start Date
November 30, 2018
Primary Completion Date
April 26, 2022
Study Completion Date
December 22, 2022
ZN-c5
ZN-c5 is a study drug
Palbociclib
Palbociclib (IBRANCE®) is an approved drug
Site 7, New York
Site 2, New York
Site 18, Belgrade
Site 19, Belgrade
Site 30, Prague
Site 21, Niš
Site 25, Cherkasy
Site 48, Bethesda
Site 20, Novi Sad
Site 24, Kropyvnytskyi
Site 50, Charleston
Site 4, Nashville
Site 26, Kryvyi Rih
Site 17, Kaunas
Site 27, Kharkiv
Site 47, St Louis
Site 29, Brno
Site 9, Sarajevo
Site 11, Tuzla
Site 1, Houston
Site 8, Houston
Site 28, Olomouc
Site 10, Banja Luka
Site 3, Tucson
Site 5, Los Angeles
Site 6, Seattle
Site 39, Saint Petersburg
Site 45, Vitebsk
Site 46, Minsk
Site 41, Pyatigorsk
Site 40, Nizhny Novgorod
Site 42, Yekaterinburg
Site 52, Omsk
Site 51, Budapest
Site 35, Kecskemét
Site 37, Pécs
Site 16, Vilnius
Site 23, Kyiv
Zeno Alpha Inc.
INDUSTRY